Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
August 16 2024 - 6:22AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 15 August 2024, London UK
Statement: Zantac (ranitidine) litigation - Florida State Court
Daubert Ruling in Wilson case
●
Florida State Court's
ruling finds in favour of GSK and other defendants, excluding
plaintiff's experts' general and specific causation testimony that
ranitidine was a significant risk factor for Wilson's prostate
cancer
●
Court's ruling is
consistent with scientific consensus that there is no consistent or
reliable evidence that ranitidine increases the risk of any
cancer
●
GSK continues to
vigorously defend itself, including against all claims in other
jurisdictions
GSK plc (LSE/NYSE: GSK) welcomes today's Daubert ruling by the
Florida State Court. In excluding plaintiffs' expert testimony as
unreliable, GSK will now seek dismissal of the upcoming Wilson case
in Florida - whereby plaintiffs alleged a causal link between
ranitidine and prostate cancer.
Today's decision echoes the December 2022 ruling by Judge Rosenberg
in the federal multidistrict litigation (MDL), which rejected all
expert evidence put forward by the plaintiffs and dismissed all MDL
cases alleging bladder, esophageal, gastric, liver, or pancreatic
cancer. Both the MDL and Florida courts have determined that the
methodology used by plaintiffs' experts is unreliable and fails to
meet the Daubert standard for scientific evidence.
Since 2019, following the 16 epidemiological studies looking at
human data regarding the use of ranitidine, the scientific
consensus is that there is no consistent or reliable evidence that
ranitidine increases the risk of any cancer. Today's ruling
reflects the state of that science and ensures that unreliable and
litigation-driven science does not enter the
courtroom.
GSK continues to defend itself vigorously, including against all
remaining claims in other jurisdictions.
Notes to Editors
* The Daubert standard, established in the U.S. Supreme Court case
Daubert v. Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993)
provides criteria for evaluating whether expert testimony is
admissible under Federal Rule of Evidence 702. Under Rule 702
and Daubert, an expert may offer testimony if he or she is
qualified by knowledge, education, training or experience in a
given area and the testimony offered is reliable, relevant and
helpful to the jury. In applying the Daubert standard, the
Court acts as a gatekeeper, ensuring that expert opinions meet
certain standards for reliability and that speculative or
unreliable opinions are not presented to the jury. In
Daubert, the Supreme Court identified four factors to guide
assessment of an expert's methodology: (1) whether the expert's
methodology has been tested or is capable of being tested; (2)
whether the theory or technique used by the expert has been
subjected to peer review and publication; (3) whether there is a
known or potential error rate of the methodology; and (4) whether
the technique has been generally accepted in the relevant
scientific community. The Daubert standard is applicable to expert
testimony in all federal cases. Many states also have adopted
standards identical to the federal Daubert standard.
The term "Daubert Standard" comes from the United States Supreme
Court case: Daubert v Merrell Dow Pharmaceuticals Inc 509 US 579
(1993).
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
GSK enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q2 Results for 2024.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: August
16, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jul 2024 to Aug 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Aug 2023 to Aug 2024